West Pharmaceutic.Services

At the Wells Fargo healthcare conference, West Pharmaceutical Services raised its forecast for 2026 organic revenue growth from 7–9% to 10–11%, supported by organic growth in the second quarter that exceeded expectations by $35 million. HVP components are driving growth and now represent more than half of revenue; Annex-1 projects, biologics and GLP-1 programs offer multi-year opportunities. Margin expansion was improved to around 200–250 basis points for the year, while the West Vantage business is being temporarily weighed down by a cyberattack and the expiration of a CGM contract. West plans roughly $250 million in CAPEX, is focused on HVP investments, remains active in share repurchases and sees further growth potential in the Asia-Pacific region and in generics/biosimilars. » Mais em de.investing.com

West Pharmaceutical surprised in the second quarter with adjusted earnings per share of $2.37 (expectation $2.08) and revenue of $872.3 million (expectation $839.75 million, +13.8% year‑on‑year). Management raised the full‑year adjusted EPS guidance to $8.85–9.05, well above the consensus of $8.62. The outlook for the third quarter also beat analysts' expectations, pushing the stock in premarket trading to a new yearly high. » Mais em de.investing.com

West Pharmaceutical has completed the sale and transfer of manufacturing and supply rights and the associated facilities for the SmartDose 3.5‑mL on‑body delivery system. The company will continue development and production of other SmartDose versions, including the SmartDose 10‑mL system designed for larger volumes. West operates 50 sites worldwide, reported net sales of USD 3.07 billion for 2025, and its stock trades near its 52‑week high; analysts point to a high P/E ratio of 48.5. » Mais em de.investing.com

West Pharmaceutical Services reports significant progress in restarting its global production after a cyberattack discovered in early May. Shipping and receiving for high value products, standard packaging and HVP delivery devices have largely been restored, and manufacturing is being ramped up in stages at all sites, including the Eschweiler plant. The company emphasizes that ensuring supply continuity for customers is a priority while the investigation into the nature and scope of the incident continues. » Mais em de.investing.com

Shares of West Pharmaceutical Services rose to a 52-week high of $322.40, reflecting sustained investor confidence. The company reported revenue and earnings beats in the first quarter and raised its full-year forecast, now expecting organic growth of 7–9%. Analysts lifted several price targets, while valuations point to a high P/E of 43 and notes of possible overvaluation. Shareholders elected eleven directors and approved executive compensation at the annual meeting. » Mais em de.investing.com